zurück

Dupilumab (new indication: atopic dermatitis for patients 6 months to 5 years of age)

 

Subject:

  • Active Substance: Dupilumab
  • Name: Dupixent®
  • Therapeutic area: Atopic dermatitis
  • Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

 

Time table:

  • Start: 01.04.2023
  • Final decision by G-BA: 21.09.2023

 

Final decision:

  1. Children whose clinical disease does not resemble that of adults: Hint for a non-quantifiable additional benefit
  2. Children whose clinical disease does not sufficiently resemble that of adults: No additional benefit proved